370 related articles for article (PubMed ID: 24324033)
1. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
[TBL] [Abstract][Full Text] [Related]
2. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
3. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
Fornari F; Milazzo M; Chieco P; Negrini M; Marasco E; Capranico G; Mantovani V; Marinello J; Sabbioni S; Callegari E; Cescon M; Ravaioli M; Croce CM; Bolondi L; Gramantieri L
J Pathol; 2012 Jul; 227(3):275-85. PubMed ID: 22262409
[TBL] [Abstract][Full Text] [Related]
4. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
[TBL] [Abstract][Full Text] [Related]
5. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
7. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
8. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
9. Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.
Jung HS; Seo YR; Yang YM; Koo JH; An J; Lee SJ; Kim KM; Kim SG
Cell Signal; 2014 Jul; 26(7):1456-65. PubMed ID: 24631529
[TBL] [Abstract][Full Text] [Related]
10. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
11. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB.
Zhang Q; Cao LY; Cheng SJ; Zhang AM; Jin XS; Li Y
Oncol Rep; 2015 Mar; 33(3):1335-41. PubMed ID: 25591821
[TBL] [Abstract][Full Text] [Related]
12. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
[TBL] [Abstract][Full Text] [Related]
13. CCAT2 contributes to hepatocellular carcinoma progression via inhibiting miR-145 maturation to induce MDM2 expression.
Niu C; Wang L; Ye W; Guo S; Bao X; Wang Y; Xia Z; Chen R; Liu C; Lin X; Huang X
J Cell Physiol; 2020 Sep; 235(9):6307-6320. PubMed ID: 32037568
[TBL] [Abstract][Full Text] [Related]
14. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
17. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop.
Xia C; Shui L; Lou G; Ye B; Zhu W; Wang J; Wu S; Xu X; Mao L; Xu W; Chen Z; Liu Y; Zheng M
Sci Rep; 2017 Jun; 7(1):4396. PubMed ID: 28667294
[TBL] [Abstract][Full Text] [Related]
18. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
[TBL] [Abstract][Full Text] [Related]
19. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR.
Jiang D; Cho WC; Li Z; Xu X; Qu Y; Jiang Z; Guo L; Xu G
Biomed Pharmacother; 2017 Dec; 96():535-544. PubMed ID: 29032337
[TBL] [Abstract][Full Text] [Related]
20. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
